Relay Therapeutics (RLAY) Shares Outstanding (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Shares Outstanding data on file, last reported at $189.2 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $189.2 million, up 10.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $189.2 million (up 10.98% YoY), and the FY2025 annual result was $173.9 million, up 3.64% from the prior year.
• Shares Outstanding rose to $189.2 million in Q1 2026 per RLAY's latest filing, from $173.9 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $189.2 million in Q1 2026 and troughed at $108.4 million in Q1 2022.
• A 5-year average of $143.0 million and a median of $132.3 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding gained 1.95% in 2023, then surged 35.5% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $121.1 million in 2022, then gained by 5.24% to $127.5 million in 2023, then jumped by 31.61% to $167.8 million in 2024, then grew by 3.64% to $173.9 million in 2025, then gained by 8.82% to $189.2 million in 2026.
• Business Quant data shows RLAY's Shares Outstanding at $189.2 million in Q1 2026, $173.9 million in Q4 2025, and $172.6 million in Q3 2025.